Residual C-peptide in type 1 diabetes: what do we really know?

Area of Science:

• Endocrinology
• Immunology
• Metabolic Diseases

Background:

• Connecting peptide (C-peptide) is co-secreted with insulin and reflects endogenous insulin production.
• Residual C-peptide secretion is clinically significant in type 1 diabetes (T1D).
• The traditional Eisenbarth model posits rapid, complete beta-cell loss in T1D.

Purpose of the Study:

• To review the clinical benefits of residual insulin secretion in T1D.
• To present current data on the natural history of insulin secretion in individuals with or at risk for T1D.
• To explore the complexity of beta-cell function beyond the traditional model.

Main Methods:

• Literature review of studies on C-peptide and T1D.
• Analysis of recent data regarding natural history of insulin secretion.
• Discussion of clinical implications of residual beta-cell function.

Main Results:

• Residual C-peptide secretion remains a valuable indicator of beta-cell function in T1D.
• Accumulating evidence indicates a more nuanced progression of beta-cell loss than previously understood.
• The natural history of insulin secretion in T1D is more complex than the linear loss model suggests.

Conclusions:

• Residual insulin secretion, measured by C-peptide, holds significant clinical importance in T1D management.
• The natural history of beta-cell function in T1D is more intricate, requiring updated understanding for research and clinical practice.
• Further research into the complexities of beta-cell function is crucial for advancing T1D prevention and treatment strategies.